After the successful launch of their Dermatology CRO, fast-growing healthcare company, Vial, has disclosed plans to launch an Ophthalmology CRO. The company’s announcement comes ahead of the one of the largest ophthalmology research conferences in the world, ARVO 2022.
Vial is a next-generation CRO on a mission to disrupt the clinical trials industry with best-in-class study management and CRO services. The new Ophthalmology CRO will distinguish itself by leveraging Vial’s nationwide site network of top investigators to ensure faster, higher-quality trial outcomes for sponsors. In addition, their tech-enabled trial management system, streamlined study startup processes, centralized pre-screening call center, and an unparalleled approach to patient recruitment will successfully deliver a superior CRO experience.
“Our mission at Vial has stayed the same since day one — running clinical trials faster and more efficiently in order to drive results for sponsors in record time. We are excited to keep up the momentum we’ve created with our Dermatology CRO and replicate its success in the ophthalmology industry”, said Jason Shuris, Vial’s Head of Sales. Jason brings 11 years of CRO experience to the Vial CRO team. Prior to joining Vial, he held senior positions at both ophthalmology and dermatology focused CROs, namely Ora and Innovaderm.
Vial is currently developing their ophthalmology site network, which will power the CRO, by partnering with top ophthalmologists across both anterior and posterior segment specialties in preparation for the expansion.
